Allscripts Healthcare Stock
Your prediction
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allscripts Healthcare | - | - | - | - | - | - | - |
| Simulations Plus | 0.630% | 1.923% | 2.581% | -57.027% | 3.247% | -57.027% | -58.594% |
| MicroVision Inc | -5.380% | -17.070% | -12.959% | -79.616% | -70.159% | -93.122% | -98.035% |
| Fluidigm Corp. | 0.000% | -2.685% | 13.281% | -36.404% | -31.604% | -64.806% | -86.079% |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at TD Cowen from $26.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat